AstraZeneca and Daiichi Sankyo’s Enhertu Improves PFS in First-Line HER2-Mutant Advanced NSCLC in Phase III DESTINY-Lung04
International Urology Cancer Summit and OncoDaily Announce Strategic Partnership
Using Lung Function Data to Refine Pulmonary Toxicity Risk Before Thoracic Radiotherapy
Evelyn H. Lauder at 90: A Legacy That Transformed Breast Cancer Research
DESTINY-Lung04: Enhertu Improves First-Line PFS in HER2-Mutant NSCLC
AstraZeneca Discontinues Phase III eVOLVE-Lung02 Trial of Volrustomig Plus Chemotherapy in Metastatic NSCLC
10 Must-Read Posts In GU Oncology This Week
Vivek Subbiah: Rethinking the Unified Cancer of Unknown Primary Concept
Aren Karapetyan is a practicing radiation oncologist at Erebuni Radiotherapy Center and an active media professional serving as a content creator and editor-in-chief for OncoDaily RT. His clinical work focuses on specialized radiotherapy for head and neck as well as genitourinary cancers also he evaluates new research as a peer reviewer.
